Recently, HANSOH PHARMA released its performance results for the first half of 2025. The company achieved revenue of approximately 7.434 billion RMB in the first half, representing an increase of about 14.3% compared to the same period last year. Innovation drugs and cooperative product sales revenue reached approximately 6.145 billion RMB (+22.1%), accounting for about 82.7% of total revenue. R&D investment was approximately 1.441 billion RMB (+20.4%), representing about 19.4% of total revenue. Profit reached approximately 3.135 billion RMB (+15.0%), with basic earnings per share of approximately 0.53 RMB (+14.8%).
HANSOH PHARMA, formerly known as Jiangsu Haosen Pharmaceutical, was established in 1995 and is a leading innovation-driven pharmaceutical enterprise in China, focusing on major disease treatment areas including anti-tumor, anti-infection, central nervous system, metabolic and autoimmune diseases. The company has been ranked among the top 100 global pharmaceutical companies for consecutive years and among the top three Chinese pharmaceutical companies with the best R&D product pipeline. It is a National Key High-tech Enterprise and National Technology Innovation Demonstration Enterprise, listed on the Hong Kong Stock Exchange in June 2019.
Currently, the company has established four R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, with over 1,900 professional R&D personnel. It has built a comprehensive R&D system covering the entire process from frontier information collection, compound design and screening, pharmacological and toxicological research to clinical medical research, and has created multiple national-level R&D institutions including National Enterprise Technology Center, Postdoctoral Research Station, and National Key Laboratory.
Through years of accumulation, HANSOH PHARMA has developed efficient innovative drug R&D capabilities covering ADC, synthetic peptides, siRNA, bispecific antibodies, and small molecules. Currently, over 40 candidate innovative drug projects are undergoing more than 70 clinical trials, forming a rich and competitive R&D pipeline.
HANSOH PHARMA stated that the increases in revenue, profit, and basic earnings per share during the reporting period were mainly due to increased sales revenue from innovation drugs and cooperative products. Specifically, anti-tumor drugs, anti-infection drugs, central nervous system drugs, and metabolic and other disease drugs generated revenues of 4.531 billion RMB, 735 million RMB, 768 million RMB, and 1.400 billion RMB respectively, accounting for 60.9%, 9.9%, 10.4%, and 18.8% of total revenue respectively.
HANSOH PHARMA updated its R&D pipeline progress. During the reporting period, HANSOH PHARMA was conducting over 70 clinical trials for innovative drugs, involving more than 40 candidate innovative drugs. Among them, 7 candidate innovative drugs initiated new Phase I clinical trials during the reporting period, including: ①small molecule BTK inhibitor HS-10561 (chronic spontaneous urticaria), ②ADC drug HS-20108 (advanced solid tumors such as small cell lung cancer, neuroendocrine tumors, etc.), ③EGFR/c-Met ADC drug HS-20122 (advanced solid tumors such as NSCLC, head and neck squamous cell carcinoma or colorectal cancer, etc.), ④HS-10542 (paroxysmal nocturnal hemoglobinuria and IgA nephropathy), ⑤HS-10510 (primary hypercholesterolemia and mixed dyslipidemia), ⑥small molecule KRAS G12D inhibitor HS-10529 (KRAS G12D mutated advanced solid tumors such as pancreatic cancer, colorectal cancer, NSCLC, etc.), and ⑦HS-20118 (moderate to severe plaque psoriasis).
Three innovative drugs initiated Phase III pivotal registration clinical trials, including: ①B7-H3 ADC drug HS-20093 (bone and soft tissue sarcoma), ②B7-H4 ADC drug HS-20089 (ovarian cancer), and ③IL-23p19 monoclonal antibody HS-20137 in cooperation with Immunotech (moderate to severe plaque psoriasis).